Lexeo Therapeutics (LXEO)

• Market cap: $386M
• 1 day: -2.38%
• 5 days: 4.9%
• 1 month: -4.28%
• 3 months: -11.19%
• 6 months: -52.87%
• Year to date: -48.8%
• 1 year: 24.24%
• 5 years: -51.04%
• 10 years: -51.04%
• Sector: Healthcare
• Industry: Biotechnology

About: Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Employees: 59